B O O K - American College of Rheumatology

wednesday
4:30 PM
2168. ALD518 (BMS945429), a High Affinity Monoclonal
Antibody Directed Against Interleukin-6, Reduces Disease
Activity and Achieves Remission in Patients with Rheumatoid
Arthritis and Inadequate Response to Methotrexate.
Philip Mease 5 , Vibeke Strand 4 , Levan Shalamberidze 6 ,
Aleksandar Dimic 3 , Richard Aranda 2 and Jeff Smith 1 , 1 Alder
Biopharmaceuticals Inc., Bothell, WA, 2 Bristol-Myers Squibb,
Princeton, NJ, 3 Institute of Rehabilitation and Treatment, Niska
Banja, Serbia, 4 Stanford University, Palo Alto, CA, 5 Swedish
Medical Center and University of Washington, Seattle, WA, 6 V.
Tsitlanadze Scientific Practical Centre of Rheumatology, Tbilisi,
Georgia
4:45 PM
2169. Efficacy and Safety of Ocrelizumab in Patients with Active
Rheumatoid Arthritis Who Have an Inadequate Response to at
Least One TNF Inhibitor: Results from the Phase III SCRIPT Trial.
Paul P. Tak 1 , Philip J. Mease 7 , Mark C. Genovese 8 , Joel M.
Kremer 9 , Boulos Haraoui 4 , Yoshiya Tanaka 10 , Clifton O. Bingham 5 ,
Ali Ashrafzadeh 2 , Helen Travers 6 , Simon Safa-Leathers 6 , Sanjeev
Kumar 6 and Wolfgang Dummer 3 , 1 Academic Med Ctr/Univ of
Amsterdam, Amsterdam, The Netherlands, 2 Genentech, San
Francisco, CA, 3 Genentech, 4 Institut de Rhumatologie, Montreal,
QC, Canada, 5 Johns Hopkins University, Baltimore, MD, 6 Roche,
7
Seattle Rheumatology Associate, Seattle, WA, 8 Stanford Univ,
Sunnyvale, CA, 9 The Center for Rheumatology, Albany, NY, 10 U
Occupa & Environ Hlth, Kitakyushu, Japan
5:00 PM
2170. Safety, Tolerability, Pharmacokinetics,
Pharmacodynamics and Efficacy of the Monoclonal Antibody
ASK8007 Blocking Osteopontin in Patients with Rheumatoid
Arthritis in a Randomized, Placebo-Controlled, Combined Firstin-Man
and Proof-of-Concept Study.
M. Boumans 5 , J. Houbiers 1 , P. Verschueren 10 , A. Ishikura 2 , R.
Westhovens 10 , E. Brouwer 4 , B. Rojkovich 8 , S. Kelly 3 , M. Den
Adel 2 , J. Isaacs 7 , J. Gomez-Reino 9 , G. Holtkamp 2 , D. Gerlag 6 and
P. Tak 6 , 1 Astellas Pharma Global Development, the Netherlands
and Japan, Leiderdorp, The Netherlands, 2 Astellas Pharma
Global Development, the Netherlands and Japan, 3 Centre for
Experimental Medicine and Rheumatology, Queen Mary’s School
of Medicine, London, 4 Department Rheumatology, University
Medical Center Groningen, Groningen, The Netherlands,
5
Division of Clinical Immunology and Rheumatology, Academic
Medical Center / University of Amsterdam, Amsterdam,
Noord-Holland, The Netherlands, 6 Division of Clinical
Immunology and Rheumatology, Academic Medical Center
/ University of Amsterdam, Amsterdam, The Netherlands,
7
Musculoskeletal Research Group, Institute of Cellular Medicine,
Newcastle University, Newcastle upon Tyne, United Kingdom,
8
Rheumatology, Buda Charity Hospital, Budapest, Hungary,
9
Rheumatology, Hospital Clinico Universitario, Santiago de
Compostela, Spain, Santiago, Spain, 10 University Hospital Leuven,
Leuven, Belgium
5:15 PM
2171. Tasocitinib (CP-690,550) Appears To Be Effective
and Tolerated When Administered Either as Long-Term
Monotherapy or on Background Methotrexate in Patients with
Rheumatoid Arthritis.
Carol A. Connell 1 , Richard Riese 2 , Susan Wood 2 , John Bradley 2
and Samuel H. Zwillich 2 , 1Pfizer Inc, New London, CT, 2 Pfizer Inc.
5:30 PM
2172. A Randomized Dose-Ranging, Placebo-Controlled Study
of INCB028050, a Selective JAK1 and JAK2 Inhibitor in Subjects
with Active Rheumatoid Arthritis.
Maria W. Greenwald 1 , Rosanne Fidelus-Gort 4 , Rich Levy 4 , Jinjin
Liang 4 , Kris Vaddi 4 , William V. Williams 3 , Robert Newton 4 ,
Swamy Yeleswaram 4 , Robert Flores 4 , Edward McKeever 4 , James
Rodgers 4 , Stacey Shepard 4 , Pierre-Yves Berclaz 2 , Chin Hyok Lee 2
and Monica E. Luchi 3 , 1 Desert Medical, Palm Desert, CA, 2 Eli
Lilly & Company, 3 Incyte Corporation, Wilmington, DE, 4 Incyte
Corporation
5:45 PM
2173. A Large, Phase IIIb Non-Inferiority Trial of Subcutaneous
(SC) Abatacept Compared with Intravenous (IV) Abatacept, in
Patients with Rheumatoid Arthritis (RA).
Mark C. Genovese 13 , Jose Arturo Covarrubias 3 , Gustavo Leon 5 ,
Eduardo F. Mysler 8 , Mauro W. Keiserman 10 , Robert M. Valente 9 ,
Peter Nash 15 , J. Abraham Simon 2 , Wieslawa Porawska 11 , Jane H.
Box 14 , Clarence W. Leggerton 6 , Evgeny Nasonov 7 , Patrick Durez 4 ,
Richard Aranda 1 , Ramesh Pappu 1 , Ingrid Delaet 1 , Julie Teng 1 and
Rieke Alten 12 , 1 Bristol-Myers Squibb Co, Princeton, NJ, 2 Centro
de Especialidades Médicas, Merida, Mexico, 3 Centro Medico de
Las Americas, Merida, Yucatan, Mexico, 4 Cliniques Universitaires
Saint-Luc, Université Catholique de Louvain, Brussels, Belgium,
5
De Ginecologia Y Reproduccion, Lima, Peru, 6 Department of
Medicine, Medical University of South Carolina, Charleston,
SC, 7 Institute of Rheumatology, Moscow, Russia, 8 Organización
Médica de Investigación, Buenos Aires, Argentina, 9 Physician
Research Collaboration, Lincoln, Lincoln, NE, 10 Pontificial Catholic
University, School of Medicine, Porto Alegre, Brazil, 11 Poznanski
Osrodek Medyczny Novamed, Ponzan, Poland, 12 Schlosspark-
Klinik, Charité, University Medicine Berlin, Department of
Internal Medicine II Rheumatology, Berlin, Germany, 13 Stanford
University, Palo Alto, Sunnyvale, CA, 14 The Arthritis Clinic &
Carolina Bone & Joint, Charlotte, NC, 15 University of Queensland,
Brisbane, Australia
A406
Sjögren’s Syndrome
Moderators: Alan N. Baer, MD; Johns Hopkins University;
Baltimore, MD
Athanasios G. Tzioufas, MD; Medical School-University of
Athens; Athens, Greece
4:30 PM
2174. Receptor-Mediated Small Interfering RNA Delivery in
Sjögren’s Syndrome.
Kaleb M. Pauley, Adrienne E. Gauna and Seunghee Cha,
University of Florida, Gainesville, FL
4:45 PM
2175. Structure and Antigenicity of the Ro/La RNP Particle.
hY1 RNA Differentiates the Recognition of Epitopes in Systemic
Lupus Erythematosus and Sjögren’s Syndrome.
John G. Routsias1, Nikos C. Kyriakidis 1 , Stathis Kotsakis 1 and
Athanasios G. Tzioufas 2 , 1 Department of Pathophysiology,
Medical School, University of Athens, Athens, Greece, 2 Medical
School-Univ of Athens, Athens, Greece
126
2010 Program Book